BALCHEM CORP: management transactions · United States · SEC (Form 4)

About BALCHEM CORP

Balchem Corp. (ticker BCPC) is a U.S.-listed company traded on NASDAQ, making it a relevant name for investors looking at U.S. equity exposure. Headquartered in Montvale, New Jersey, the company traces its roots back to 1967, when it was founded by entrepreneurs and investors. Over time, Balchem has developed into a specialist provider of performance ingredients and enabling technologies, with a business model centered on formulation science, encapsulation, chelation, and nutrition-related chemistry rather than commodity chemical exposure.([balchem.com](https://balchem.com/our-company/)) Today, Balchem operates through three main reporting segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Human Nutrition & Health supplies customized ingredient systems for food and beverage applications, supplements, and certain pharmaceutical uses, alongside key nutrients and delivery systems. Animal Nutrition & Health is a core strategic franchise and is described by the company as a global leader in choline production, nutrient encapsulation, chelated minerals, and functional ingredients used across ruminants, swine, poultry, aquaculture, and companion animals. Specialty Products covers more technical applications, including performance gases and other industrial end markets.([sec.gov](https://www.sec.gov/Archives/edgar/data/0000009326/000000932626000016/exhibit991-q12026.htm?utm_source=openai)) From a competitive standpoint, Balchem’s appeal lies in its niche leadership and technical differentiation. The company emphasizes long-standing expertise, proprietary product systems, and a broad manufacturing footprint, which it says includes 22 global manufacturing locations and 8 global R&D technology centers. That scale supports customer intimacy, product innovation, and supply-chain resilience while allowing Balchem to serve multiple end markets from a single platform of specialty ingredients.([balchem.com](https://balchem.com/our-company/)) The product portfolio is anchored by branded and specialty platforms such as VitaCholine®, K2VITAL™, Optifolin+®, OptiMSM®, and Balchem’s microencapsulation offerings including BakeShure®, ConfecShure®, and MeatShure®. These brands are important because they reinforce Balchem’s positioning as a solutions provider rather than a simple ingredient supplier, helping the company differentiate on performance, formulation support, and end-use benefits. The company has also been investing in brand-building and customer-facing digital assets, including new product brand sites launched in 2025.([balchem.com](https://balchem.com/wp-content/uploads/2025/04/Balchem-Q1-2025-Earnings-Release.pdf)) Recent corporate developments underscore this strategic direction. In December 2025, Balchem announced a new high-capacity microencapsulation manufacturing facility in Orange County, New York, expected to open in 2027 and designed to expand capacity for its food-ingredient technologies. Management said the project builds on more than five decades of expertise and strengthens the company’s foothold in the U.S. In parallel, Balchem has continued to report solid operating momentum, with record quarterly sales and EBITDA in 2025, driven by growth across all three segments. The company also highlighted EU anti-dumping duties on choline chloride imports from China, a potentially favorable development for its European choline-related business.([balchem.com](https://balchem.com/news/hnh-new-microencapsulation-facility/))